DrugPatentWatch Database Preview
Avid Radiopharms Inc Company Profile
What is the competitive landscape for AVID RADIOPHARMS INC, and when can generic versions of AVID RADIOPHARMS INC drugs launch?
There are two US patents protecting AVID RADIOPHARMS INC drugs.
There are thirty-seven patent family members on AVID RADIOPHARMS INC drugs in thirty-one countries and thirteen supplementary protection certificates in thirteen countries.
Summary for Avid Radiopharms Inc
| International Patents: | 37 |
| US Patents: | 2 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Avid Radiopharms Inc
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-003 | Apr 6, 2012 | RX | Yes | Yes | 8,506,929 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-002 | Apr 6, 2012 | RX | Yes | Yes | 7,687,052 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-003 | Apr 6, 2012 | RX | Yes | Yes | 7,687,052 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Avid Radiopharms Inc | AMYVID | florbetapir f-18 | SOLUTION;INTRAVENOUS | 202008-001 | Apr 6, 2012 | DISCN | No | No | 7,687,052 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Non-Orange Book US Patents for Avid Radiopharms Inc
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 8,840,866 | Styrylpyridine derivatives and their use for binding and imaging amyloid plaques | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Avid Radiopharms Inc Drugs
Supplementary Protection Certificates for Avid Radiopharms Inc Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 1 | Finland | ➤ Sign Up | |
| 0130016 00076 | Estonia | ➤ Sign Up | PRODUCT NAME: FLORBETAPIIR (18F);REG NO/DATE: K(2013)137 (LOPLIK) 14.01.2013 |
| 232 | Luxembourg | ➤ Sign Up | PRODUCT NAME: FLORBETAPIR (18 F) |
| /2013 | Austria | ➤ Sign Up | PRODUCT NAME: FLORBETAPIR (18F); REGISTRATION NO/DATE: EU/1/12/805 20130114 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
